Treatment for dupuytren's disease
View Patent ↗Musculoskeletal fibroproliferative disorders, such as Dupuytren's disease may be treated by administering locally a TNF-α antagonist. TNF-α antagonists find particular utility in inhibiting the progression of early disease state Dupuytren's disease and other musculoskeletal fibroproliferative disorders and, in combination with extracellular matrix degradation agents (such ascollagenase or matrix metalloproteinase I), treating advanced disease state Dupuytren's disease and, in particular inhibiting recurrence.
1. A method for treating a patient with early disease state Dupuytren's disease comprising injecting an amount of a TNF-α antagonist effective to treat the patient directly into one or more clinical or histological nodules of the patient.
2. A method according to claim 1 , wherein the TNF-α antagonist is selected from one or more of Infliximab, Adalimumab, Certolizumab pegol, Golimumab or Etanercept.
3. A method according to claim 1 , wherein the TNF-α antagonist is an anti-TNF-α antibody.
4. A method according to claim 1 , wherein the TNF-α antagonist is injected into clinical nodules.
5. A method according to claim 1 , wherein the TNF-α antagonist is Infliximab.
6. A method according to claim 1 , wherein the TNF-α antagonist is Adalimumab.
7. A method according to claim 1 , wherein the TNF-α antagonist is Certolizumab pegol.
8. A method according to claim 1 , wherein the TNF-α antagonist is Golimumab.
9. A method according to claim 1 , wherein the TNF-α antagonist is Etanercept.